A Study to Determine the Improvement of the Symptoms of Benign Prostatic Hyperplasia (BPH) When Switching Subjects From Proscar to Avodart
Phase 4
- Conditions
- Benign Prostatic Hyperplasia
- Registration Number
- NCT00690950
- Lead Sponsor
- Urologic Consultants of Southeastern PA
- Brief Summary
Hypothesis: Dutasteride will perform better than finasteride in decreasing prostate volume, improving symptoms based on International Prostate Symptom score,and lower pvr based on the scientific information that dutasteride inhibits both Type I and II 5-alpha-reducatase vs. finasteride which only inhibits the Type II enzyme
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Male
- Target Recruitment
- 50
Inclusion Criteria
- Male
- Age 50-80
- On finasteride for no less than 12 months
- Willing to undergo all necessary test in the 12 month evaluation
Exclusion Criteria
- History of medication non-compliance
- Unwillingness to undergo/tolerate 2 blood draws
- Unwillingness to tolerate/undergo 2 TRUSP
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Laboratory parameters: including serum testosterone, DHT level and PSA 12 months
- Secondary Outcome Measures
Name Time Method volume measurements of TRUSP and PVR 12 months A decrease in the AUASI 12 months
Trial Locations
- Locations (1)
Urologic Consultants of Southeastern PA
🇺🇸Bala Cynwyd, Pennsylvania, United States
Urologic Consultants of Southeastern PA🇺🇸Bala Cynwyd, Pennsylvania, United States